SHL Telemedicine Ltd. (SWX: SHLTN) has obtained US Food and Drug Administration (FDA) marketing approval for its Smartheart ECG for smartphones. The Smartheart is available for iPhones, Android devices and BlackBerry. The device previously obtained EU CE Mark certification.
The Smartheart enables the user to perform a hospital-grade ECG and send the results in real time to the company's telemedicine call center, to his personal physician or cardiologist, upload it to his personal medical record, or send it to a hospital for medical diagnosis. The ECG results can be viewed and examined any time, on the smartphone, through secured access.
SHL cites studies which claim that m-health technologies will revolutionize the health services market, and that this market is expected to grow from $500 million in 2010 to over $8 billion in 2018.
SHL co-CEO Erez Alroy said, "The Smartheart transforms any smartphone into a Hospital-Grade ECG that allows the user to perform a quick and simple test, equal in quality to a professional hospital ECG examination. We believe the Smartheart is a technological breakthrough, positioning SHL at the forefront of the mHealth market, opening up access to new target audiences, both in existing and new markets."
SHL's share price rose 3.7% in morning trading on the Swiss Stock Exchange to CHF 7, giving a market cap of CHF 74 million.
Published by Globes [online], Israel business news - www.globes-online.com - on June 26, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012